Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    3 0 0 0

Revue du rhumatisme
Volume 71, n° 5
pages 327-329 (mai 2004)
Doi : 10.1016/j.rhum.2003.10.009
Received : 22 August 2003 ;  accepted : 27 October 2003
Rotation des anti-TNF- : quelles données ?
Switching between Anti-TNF-α Agents: What is the evidence? " onClick="javascript:init_clueTip($j(this));" rel=".tooltip-art-idFN0">

Bernard  Combe *
Service d'immunorhumatologie, hôpital Lapeyronie, 371, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex 5, France 

*Auteur correspondant.

Mots clés  : Traitement anti-TNF ; Pharmacocinétique ; Étanercept ; Adalimumab ; Infliximab ; Rotation de traitement.

Mots clés  : Anti-TNF therapy ; Pharmacokinetis ; Etanercept ; Adalimumab ; Infliximab ; Treatment switching.

  Pour citer cet article, utiliser ce titre en anglais et sa référence dans le même volume de Joint Bone Spine.

© 2003  Published by Elsevier Masson SAS.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline